LitAlert ~~ GeneLit.com

    • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    • Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea AD, Swisher EM, Matulonis UA, Wulf GM. Mayer EL.
    • Clin Cancer Res. 2022 Feb 11:clincanres.3045.2021. doi: 10.1158/1078-0432.CCR-21-3045. Epub ahead of print.
    • Niraparib Related Pulmonary Embolism during the Treatment of BRCA Mutant Advanced Ovarian Cancer.
    • Wei Q, Chen D, Liu Y.
    • Front Oncol. 2022 Feb 11;10:853211. doi: 10.3389/fonc.2022.853211.
    • Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
    • Nie X, Chen X, Jiang Y, Zhong Y, Chen T, Cheng W.
    • Medicine (Baltimore). 2022 Feb 11;101(6):e28712. doi: 10.1097/MD.0000000000028712.
    • Olaparib for ovarian cancer: a single-institution, multi-site qualitative study.
    • Martin NA, Hanna M, Ehret C, Asiedu G, Jatoi A.
    • Support Care Cancer. 2022 Feb 11. doi: 10.1007/s00520-022-06879-w. Epub ahead of print.
    • Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    • Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY.
    • Gynecol Oncol. 2022 Feb 10:S0090-8258(22)00086-5. doi: 10.1016/j.ygyno.2022.02.002. Epub ahead of print.